Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years – FiercePharma

by

  1. Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years FiercePharma
  2. Pfizer and Astellas Seek Expanded Label for Expensive Prostate Cancer Drug BioSpace
  3. Enzalutamide plus leuprolide boosts metastasis-free survival in nmHSPC Urology Times
  4. Pfizer, Astellas’ Xtandi meets main goal in phase 3 trial for prostate cancer subtype Seeking Alpha
  5. Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer PR Newswire
  6. View Full Coverage on Google News

Read original article here

Leave a Comment